aducanumab
FDA fast track designation for Biogen’s investigational Alzheimer’s treatment
September 2, 2016Medical Communications, Research and Development Alzheimer's, Alzheimer’s, Biogen, FDA, aducanumab, fast track
Biogen has announced that its investigational Alzheimer’s disease treatment aducanumab has been granted fast track designation by the FDA. The …
Neurimmune kicks off late-stage Alzheimer’s study
September 9, 2015Research and Development Alzheimer's disease, Biogen, Neurimmune, aducanumab, neurology
Neurimmune and its development partner Biogen are beginning a Phase III study of the companies’ potential Alzheimer’s treatment aducanumab. The …
Biogen shortens name and posts positive Alzheimer’s results
March 23, 2015Sales and Marketing AD, Alzheimer's, BIIB037, Biogen, MS, Parkinson's, aducanumab, idec
Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …
